- Home
- CCM vs NRBO Comparison
CCM vs NRBO Comparison
Compare CCM & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- NRBO
- Stock Information
- Founded
- CCM 1997
- NRBO N/A
- Country
- CCM China
- NRBO United States
- Employees
- CCM N/A
- NRBO N/A
- Industry
- CCM Medical/Nursing Services
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- CCM Health Care
- NRBO Health Care
- Exchange
- CCM Nasdaq
- NRBO Nasdaq
- Market Cap
- CCM 25.1M
- NRBO 27.9M
- IPO Year
- CCM 2009
- NRBO N/A
- Fundamental
- Price
- CCM $5.08
- NRBO $2.46
- Analyst Decision
- CCM
- NRBO Strong Buy
- Analyst Count
- CCM 0
- NRBO 1
- Target Price
- CCM N/A
- NRBO $10.00
- AVG Volume (30 Days)
- CCM 6.1K
- NRBO 34.1K
- Earning Date
- CCM 11-22-2024
- NRBO 11-07-2024
- Dividend Yield
- CCM N/A
- NRBO N/A
- EPS Growth
- CCM N/A
- NRBO N/A
- EPS
- CCM N/A
- NRBO N/A
- Revenue
- CCM $64,910,622.00
- NRBO N/A
- Revenue This Year
- CCM N/A
- NRBO N/A
- Revenue Next Year
- CCM N/A
- NRBO N/A
- P/E Ratio
- CCM N/A
- NRBO N/A
- Revenue Growth
- CCM N/A
- NRBO N/A
- 52 Week Low
- CCM $3.80
- NRBO $2.08
- 52 Week High
- CCM $26.70
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- CCM 33.74
- NRBO 39.90
- Support Level
- CCM $4.47
- NRBO $2.37
- Resistance Level
- CCM $9.07
- NRBO $2.99
- Average True Range (ATR)
- CCM 0.72
- NRBO 0.30
- MACD
- CCM -0.32
- NRBO 0.00
- Stochastic Oscillator
- CCM 21.37
- NRBO 22.22
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high-intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.